The study investigates the comparative efficacy of ICS+LABA versus ICS+LABA+Omalizumab in patients with allergic asthma, addressing a significant unmet need in asthma management. With approximately 334 million asthma patients globally, the market for asthma therapeutics, particularly biologics like Omalizumab, is substantial and growing. The insights gained from transcriptomic analysis may lead to improved personalized treatment strategies, enhancing patient outcomes and potentially increasing market share for the involved therapies. The findings could also inform future product development and positioning against competitors in the asthma biologics space.